Our finding of extremely low Lef1 expression in ligand-dependent CRCs also argues that Lef1 levels in CRC tumor cells could serve as a biomarker for the identification of patients with CRC who may benefit from WNT ligand inhibition. This evidence concerns the gene LEF1 and neoplasm.